MPR Weekly Dose

MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn

Oct 29, 2021

The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema...

MPR Weekly Dose 97 - ‘Mix and Match’ Boosters Authorized; Biosimilar to Humira; Nasal Spray for Dry Eye Disease; Novel Pain Treatment; Opioid Overdose Treatment

Oct 22, 2021

This week: big news announced in COVID-19, with the FDA stating that mixing and matching of vaccines for the booster dose is authorized. The first interchangeable biosimilar to Humira is approved. Also there’s approvals for dry eye disease, pain management and opioid overdoses.

MPR Weekly Dose 96 - Updated Aspirin Recommendations; Needle-Free Warning; Isotretinoin REMS program; Pediatric Athymia Tx; EU Request for Molnupiravir; Advisory Panel Votes on Moderna Booster Shot

Oct 15, 2021

This week the USPSTF update aspirin recommendations for those 60 years and older; The FDA take a stance on needle-free devices for injecting dermal fillers; REMS requirements are updated for isotretinoin products; A new treatment approved for pediatric congenital athymia; An emergency use request submitted for an oral...

MPR Weekly Dose 95 - Interview with Dr Preeti Malani, Chief Health Officer and Professor of Medicine in the Division of Infectious Diseases at the University of Michigan

Oct 7, 2021

Dr Preeti Malani, Chief Health Officer at UM, joined us to talk about the current state of the COVID-19 pandemic, including vaccine hesitancy, mandates, boosters and how the future may unfold.